KJHP
ADAP

K.J. Harrison & Partners’s Adaptimmune Therapeutics ADAP Stock Holding History

K.J. Harrison & Partners’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-20,000
Closed -$160K – 279
2020
Q3 		$160K Hold
20,000
– – 0.03% 208
2020
Q2 		$200K Buy
+20,000
New +$126K 0.05% 179

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

K.J. Harrison & Partners's ADAP Position: Q4 2020 in Review

K.J. Harrison & Partners sold out of Adaptimmune Therapeutics (ADAP) in Q4 2020, closing a stake of 20,000 shares — an estimated $160K sold.

K.J. Harrison & Partners first reported a position in ADAP in Q2 2020 and held it in 2 quarters. The position peaked at $200K in Q2 2020. 87 funds tracked by Wall St. Rank hold ADAP as of Q4 2020.

  • K.J. Harrison & Partners reported no remaining Adaptimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
  • K.J. Harrison & Partners sold 20,000 Adaptimmune Therapeutics shares in Q4 2020, an estimated $160K.
  • K.J. Harrison & Partners first reported a position in Adaptimmune Therapeutics in Q2 2020 and held it in 2 quarters.
  • K.J. Harrison & Partners's Adaptimmune Therapeutics position peaked at $200K in Q2 2020.
  • 87 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2020.

Based on K.J. Harrison & Partners's 13F filing for Q4 2020, filed 8 Feb 2021.